Samsung’s earbuds just became hearing aids — but not yet in Britain
The FDA has cleared a hearing aid feature for Galaxy Buds 3 Pro and Buds 4 Pro. It ships in the US and “select markets” in the fourth quarter, and Samsung has not said whether the UK is one of them.
The US Food and Drug Administration has cleared Samsung’s Hearing Aid feature, allowing Galaxy Buds 3 Pro and Galaxy Buds 4 Pro to work as over-the-counter hearing aids for adults with perceived mild to moderate hearing loss.
The feature arrives in the fourth quarter of 2026 in the United States and what Samsung calls “select markets”. The company has not published the list, and the UK’s position in it is the detail British readers actually need.
What was cleared
Two things, and they are worth separating.
The first is a hearing test built into the Galaxy Buds settings, which Samsung says takes about five minutes. The second is the hearing aid function itself, which amplifies and shapes sound to compensate for the loss the test finds. Both live in the earbud settings on a compatible Galaxy phone rather than in a separate app.
Samsung says it developed the feature with the National Acoustic Laboratories and the Samsung Medical Center, with clinical validation at Vanderbilt University Medical Center, San Jose State University and the University of Memphis. Naming the validating institutions is more than most consumer audio announcements do, and it is checkable.
Eligibility is adults aged 18 and over with perceived mild to moderate hearing loss. That word is carrying weight: the FDA’s over-the-counter hearing aid category, created in 2022, exists precisely so people can buy a device without a clinical diagnosis. It is not intended for severe loss, and it is not a substitute for an audiologist where one is warranted.
Why this matters more than a feature drop
Hearing aids are expensive, and the gap between needing one and getting one is measured in years. The category was opened up in the US specifically to attack that gap by removing the prescription requirement. Every major earbud maker has been circling it since.
The relevant number is not the earbuds’ price but the alternative’s. Prescription devices routinely run to thousands. A pair of flagship earbuds that already exist in someone’s pocket, doing a clinically validated job for a subset of users, is a genuinely different proposition — and the reason to be interested is affordability, not novelty.
The British caveat
An FDA clearance has no legal effect in the UK. Medical devices sold in Great Britain are regulated by the MHRA under its own framework, and a device cleared in the US must satisfy that framework separately before it can be marketed here as a hearing aid.
So the feature existing is not the same as the feature arriving. It may well come — Samsung ships globally and the engineering is done — but it requires a separate regulatory step that Samsung has not commented on.
Meanwhile hearing aids are available on the NHS free of charge where clinically indicated, which changes the economics considerably compared with the US market this clearance is aimed at. The British case for earbud hearing aids is convenience and stigma rather than cost, and that is a weaker driver.
Hearing is also one of the narrower, better-evidenced places consumer technology is meeting medicine. The broader claims are much further off: Google’s medical AI can now run a video consultation, but only against actors, and only as research.
We have asked Samsung whether the UK is among the “select markets” and whether it has applied for MHRA approval. We will update this piece if the company responds.